Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients - Archive ouverte HAL
Article Dans Une Revue Hematological Oncology Année : 2022

Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients

Résumé

This study reports the effectiveness of three injections of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine in 141 Allo‐HSCT recipients with a median follow‐up of 6 months post‐third shot. We demonstrate a long‐term high protection of Allo‐HSCT recipients since only 2 infections and one death related to COVID‐19 occurred.

Dates et versions

hal-04743368 , version 1 (18-10-2024)

Identifiants

Citer

Patrice Chevallier, Maxime Jullien, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, et al.. Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients. Hematological Oncology, 2022, 40 (5), pp.1097-1099. ⟨10.1002/hon.3006⟩. ⟨hal-04743368⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More